Binimetinib - CAS 606143-89-9
Catalog number: B0084-455720
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C17H15BrF2N4O3
Molecular Weight:
441.233
COA:
Inquire
Targets:
MEK
Description:
Binimetinib is an oral, highly selective MEK inhibitor.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-455720 300 mg $499 In stock
Bulk Inquiry
Purity:
>98%
Appearance:
Solid Powder
Synonyms:
MEK162; MEK-162; MEK 162; ARRY162; ARRY-162; ARRY 162; ARRY438162, Binimetinib; 5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide
MSDS:
Inquire
InChIKey:
ACWZRVQXLIRSDF-UHFFFAOYSA-N
InChI:
InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)
Canonical SMILES:
CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO
Current Developer:
Array Biopharm./Novartis.
1.Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression.
Woodfield SE1, Zhang L2, Scorsone KA3, Liu Y4,5, Zage PE6,7. BMC Cancer. 2016 Mar 1;16(1):172. doi: 10.1186/s12885-016-2199-z.
BACKGROUND: Novel therapies are needed for children with high-risk and relapsed neuroblastoma. We hypothesized that MAPK/ERK kinase (MEK) inhibition with the novel MEK1/2 inhibitor binimetinib would be effective in neuroblastoma preclinical models.
2.A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors.
Watanabe K1,2, Otsu S3, Hirashima Y3, Morinaga R3, Nishikawa K3, Hisamatsu Y3, Shimokata T4, Inada-Inoue M4, Shibata T4, Takeuchi H5, Watanabe T6, Tokushige K7, Maacke H8, Shiaro K3, Ando Y4. Cancer Chemother Pharmacol. 2016 Apr 12. [Epub ahead of print]
PURPOSE: Binimetinib is a potent, selective MEK1/2 inhibitor with demonstrated efficacy against BRAF- and RAS-mutant tumors. Retinal adverse events associated with MEK inhibitors have been reported in some cases. The aim of this study was to assess single-agent binimetinib, with detailed ophthalmologic monitoring, in Japanese patients with advanced solid tumors.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related MEK Products


CAS 606143-89-9 Binimetinib

Binimetinib
(CAS: 606143-89-9)

Binimetinib is an oral, highly selective MEK inhibitor.

CAS 934660-94-3 Cobimetinib (R-enantiomer)

Cobimetinib (R-enantiomer)
(CAS: 934660-94-3)

Cobimetinib (R-enantiomer) is a selective inhibitor of MEK. It is also known as mitogen activated protein kinase kinase (MAPKK) and is a key component of the RA...

CAS 934660-93-2 Cobimetinib

Cobimetinib
(CAS: 934660-93-2)

cobimetinib, also known as GDC-0973 and XL-518, is an orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1)...

Cobimetinib hemifumarate
(CAS: 1369665-02-0)

Cobimetinib, also known as GDC-0973 and XL-518, is a novel selective MEK inhibitor, and the IC50value against MEK1 is 4.2 nM, with potential antineoplastic acti...

CAS 212631-61-3 PD 198306

PD 198306
(CAS: 212631-61-3)

PD 198306, an amino-benzamide compound, is an orally bioavailable and potent inhibitor of MAPK kinase 1/2 (MEK1/2; IC50 = 8 nM). It inhibits isolated enzyme at ...

CAS 871700-17-3 Trametinib

Trametinib
(CAS: 871700-17-3)

Trametinib is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM and no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2.

CAS 548756-68-9 PD 334581

PD 334581
(CAS: 548756-68-9)

PD 334581, an analog of PD 184352, is an inhibitor of MEK1 that is used in biological studies to evaluate halogen bonding as a novel interaction for rational dr...

CAS 167869-21-8 PD98059

PD98059
(CAS: 167869-21-8)

PD98059 is a potent and selective inhibitor of MAP kinase kinase (also known as MAPK/ERK kinase or MEK kinase). It mediates its inhibitory properties by binding...

Chemical Structure

CAS 606143-89-9 Binimetinib

Quick Inquiry

Verification code

Featured Items